ClinicalTrials.gg
Not yet recruitingNCT07329946Updated Apr 29, 2026

Immuno-inflammatory Response of Erdosteine in COPD

An interventional study of Erdosteine and Standard of Care (SOC) in COPD, sponsored by Pierachille Santus, MD, PhD. Not yet recruiting at 1 site in Italy. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Pierachille Santus, MD, PhD · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy — 42 open to participants now, 48 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Italy.

Planned enrollment
186th of 212
30 · median 245
Started
2026
with 6 others
No phase
77 of 280
17 open now
Primary completion
2027-02
later than 24 of 47 live
Registered
270th of 280
by date

Among the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, this one is the 186th largest by planned enrollment of the 212 interventional ones that give a count, is one of 7 that started in 2026, is one of 77 with no phase, reaches primary completion later than 24 of the 47 other live ones, and was the 270th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

42 of the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) remains a major contributor to global morbidity and mortality, exposing healthcare systems to a significant economical and social load. Indeed, acute severe COPD exacerbations are the events that contribute most to the overall disease burden. Current management strategies are aimed at maximizing symptom-free periods, reduce hospitalizations, improve exercise tolerance, overall health status, and quality of life. Key pathophysiological mechanisms involved in COPD exacerbations (defined as acute worsening of respiratory symptoms) include oxidative stress, acute on chronic inflammation, and mucus hypersecretion. Agents with antioxidant, anti-inflammatory, and mucolytic properties can help reduce exacerbation frequency. Erdosteine is a new-generation mucoactive molecule developed to overcome the limitations associated with traditional mucolytics. In fact, in addition to its mucolytic effects, erdosteine exhibits antioxidant and anti-inflammatory activities and may reduce bacterial adhesion to airway surfaces - features that may be beneficial in the prevention and management of exacerbations. Preliminary clinical findings (EQUALIFE and RESTORE studies) suggest that erdosteine, in add-on to chronic inhaled therapy, can reduce exacerbation rates, shorten hospital stay, and improve health-related quality of life in patients with COPD. However, studies that have investigated the pathobiological mechanisms behind such clinical effects are lacking.

The present study was constructed in order to investigate the mechanism of action of erdosteine on inflammation, oxidative stress pathways and immune response in patients with COPD. The secondary objectives of the study are to evaluate the effect of erdosteine on lung function tests in patients with COPD; to explore the effect of erdosteine on respiratory and COPD-related symptoms in patients with COPD; to assess the effect of erdosteine on exercise tolerance in patients with COPD. In order to do so, the investigator designed a pragmatic, low intervention, two-arms, monocenter, open-label, prospective, randomized, controlled trial, set in clinical practice. A total of 30 patients will be randomized by means of a 1:1 random allocation.

The active group (15 patients) will be assigned to Treatment Arm A (Erdosteine [Esteclin®] 300 mg, 1 tablet twice daily for 30 days), while the control group (15 patients) will be assigned to Treatment Arm B (Standard of Care - current standard inhalation therapy in use).

03

Conditions studied

  • COPD

Keywords

  • COPD
  • ERDOSTEINE
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 45 years
  2. A confirmed diagnosis at least 12 months prior to enrollment
  3. Stable clinical conditions, defined as no exacerbations or respiratory infections of any severity in the last 3 months before enrollment
  4. Moderate to Severe airflow obstruction ( 30-80 %predicted post bronchodilation.
  5. No hospitalizations for any cause in the 3 months prior to enrollment
  6. Ability to perform repeatable pulmonary function tests
  7. Chronic inhaled therapy with LAMA/LABA or LAMA/LABA/ICS with no changes in dosage in the last 3 before enrollment

Exclusion criteria

Exclusion Criteria:

  1. class III and IV heart failure
  2. Unstable arrythmia
  3. Active (solid or blood)
  4. Chronic treatment with systemic or
  5. Immune depression
  6. Known to erdosteine
  7. Pregnancy or breastfeeding
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    ARM A - Erdosteine treatment

    Patients will be randomized to receive Erdosteine \[Esteclin®\] 300 mg, 1 tablet twice daily for 30 days

    Drug: Erdosteine · Drug: Standard of Care (SOC)

  • Placebo comparator
    ARM B - Standard of care

    Patients will be randomized to receive current standard inhalation therapy in use

    Drug: Standard of Care (SOC)

Interventions

  • Erdosteine tablets 300 mg, 1 tablet orally every 12 hours (twice daily) for 30 days

    Also known as: Esteclin

  • DrugStandard of Care (SOC)

    Long acting beta-2 agonists and Long acting muscarinic antagonists in association (LABA/LAMA) with or without inhaled corticosteroids (LABA/LAMA/ICS) depending on the chronic inhaled home treatment. Dosage and posology will change depending on the molecules and the devices (once daily in case of umeclidinium bromide/vilanterol 55/22 mcg or fluticasone/umeclidinium bromide/vilanterol 92/55/22 or twice daily in case of budesonide/formoterol/glycopyrronium 160/7.2/4.8 mcg and beclometasone/formoterol/glycopyrronium 87/5/9 mcg)

06

What researchers measure

Primary outcomes

  1. Changes in transcriptomics of pro-inflammatory and anti-inflammatory cytokines in COPD patients exposed to erdosteine.

    Peripheral blood will be analyzed for immunological profiling in patients treated with standard of care only and patients also exposed to Erdosteine at baseline and after 4 weeks of treatment. Cytokine/chemokine profiles will be quantified in cell culture supernatants using the Bio-Plex Pro Human Cytokine 27-plex Assay. RNA extraction from whole blood will be performed to identify expression levels of molecules involved in immune response: CARD6, CASP1, CASP4, CCL2, HLA-A, IFITM1, IFNA1, IFNAR1, IL1β, IL6, IL8, IL10, IL17, IL18, IL22, ISG20, TGF-β, NLRP3, NLRP4, VCAM1. Betaactin (ACTB) and glyceraldeyde-3-phosphate dehydrogenase (GAPDH) will be used as housekeeping genes. The results for the gene expression analyses will be presented as the average of the relative expression units (%) to an internal reference sample and normalized to the housekeeping genes GAPDH and ACTB.

    Time frame: 4 weeks

  2. Changes in transcriptomics of oxidative stress signaling pathways in COPD patients exposed to erdosteine.

    Peripheral blood will be analyzed for oxidative stress profiling in patients treated with standard of care only and patients also exposed to Erdosteine at baseline and after 4 weeks of treatment. Oxidative stress will be quantified in cell culture supernatants using the Bio-Plex Pro Human Cytokine 27-plex Assay. RNA extraction from whole blood will be performed to identify expression levels of molecules involved in oxidative stress: APOE, CAT, DUSP1, GPX2, GPX3, MPO, NOS2, NOX4, NUDT1, SOD2. Betaactin (ACTB) and glyceraldeyde-3-phosphate dehydrogenase (GAPDH) will be used as housekeeping genes. The results for the gene expression analyses will be presented as the average of the relative expression units (%) to an internal reference sample and normalized to the housekeeping genes GAPDH and ACTB.

    Time frame: 4 weeks

Secondary outcomes

  1. To assess the effect of erdosteine on mMRC dyspnea scale in patients with COPD

    Patiens will undergo the Modified British Medical Research Council Questionnaire (mMRC) at baseline and after 4 weeks of treatment with erdosteine or placebo. Modified British Medical Research Council Questionnaire (mMRC) assesses the patient's degree of chronic dyspnea with a score ranging from 0 (no dyspnea) to 4 (too much dyspnea to leave the house). The results will be expressed as absolute and relative difference in dyspnea score.

    Time frame: 4 weeks

  2. To assess the effect of erdosteine on distance covered during the six minute walk test in patients with COPD

    Patiens will undergo the Six Minutes Walk Test (6MWT) at study enrolment and after 4 weeks of treatment with erdosteine or placebo. The 6MWT will be conducted according to the 2002 American Thoracic Society (ATS) statement. For patients requiring exertional oxygen therapy, the test will be performed with supplemental oxygen. Patients will be asked to walk for 6 minutes on a flat surface, wearing a pulse oximeter. Before starting, the following parameters will be recorded: perceived dyspnoea level using the Borg scale (0-10 score), peripheral oxygen saturation (SpO2), heart rate (beats/min), and respiratory rate (breaths/min). The same parameters will be measured again at the end of the test. The distance walked, and any exercise-induced desaturation (SpO2 drop ≥4 points) will also be noted. The distance covered at the 6MWT will be measured in meters, and results will be expressed as absolute and relative difference from baseline.

    Time frame: 4 weeks

  3. To assess the effect of erdosteine on CAT (COPD assessment test) in patients with COPD

    Patiens will undergo the CAT (COPD assessment test) at baseline and after 4 weeks of treatment with erdosteine or placebo. COPD assessment test (CAT) aims to assess the impact of COPD on health status through a patient-completed questionnaire consisting of 8 items, each scored from 0 to 5. The total score ranges from 0 to 40, with higher scores indicating a greater impact of the disease on the patient's quality of life. The results will be expressed as absolute and relative difference in CAT total score.

    Time frame: 4 weeks

Other outcomes

  1. To evaluate the effect of erdosteine on dynamic lung volumes in patients with COPD

    Dynamic lung volumes, will be measured using a constant-volume body plethysmograph at study enrolment and after 4 weeks of treatment with erdosteine or placebo. The following volumes will be measured: forced expiratory volume in first second (FEV₁), forced vital capacity (FVC), slow VC, forced mid-expiratory flow at 25 and 75% of FVC (FEF25-75), expiratory reserve volume (ERV). The results will be expressed as absolute (liters) and % predicted value, and measured as absolute and relative difference from baseline.

    Time frame: 4 weeks

  2. To assess the effect of erdosteine on static volumes in patients with COPD

    Static lung volumes will be measured using a constant-volume body plethysmograph according to current recommendations (Wanger et al. Eur Respir J 2005) at baseline and after 4 weeks of treatment with erdosteine or placebo. Patients will be instructed to breathe in seated position, wearing a nose clip, while connected to a pneumotachograph, with closed cabin. The following volumes will be measured: residual volume (RV), total lung capacity (TLC), RV/TLC and intrathoracic gas volume (ITGV). ITGV will be measured close to the end-expiratory lung volume during quiet breathing to obtain functional residual capacity (FRC). The results will be expressed as absolute (liters) and % predicted value, and measured as absolute and relative difference from baseline.

    Time frame: 4 weeks

  3. To evaluate the effect of erdosteine on lung diffusion capacity in patients with COPD

    Lung diffusion capacity for carbon monoxide (DLCO) will be measured using a constant-volume body plethysmograph at study enrolment and after 4 weeks of treatment with erdosteine or placebo. DLCO, transfer factor (KCO), and alveolar volume (VA) will be measured using the single-breath technique. VA will be assessed by means of the inert gas dilution technique. The DLCO value will be corrected based on the most recent available hemoglobin value. The results will be expressed as absolute (mmol x min-1 kPa-1 for DLCO, mmol x min-1 kPa-1 1-1 for KCO, and liters for VA) and % predicted value, and measured as absolute and relative difference from baseline.

    Time frame: 4 weeks

  4. To evaluate the effect of erdosteine on specific airway resistances in patients with COPD

    Specific airway resistances (sRAW) will be measured using a constant-volume body plethysmograph according to current recommendations (Wanger et al. Eur Respir J 2005) at baseline and after 4 weeks of treatment with erdosteine or placebo. Patients will be instructed to breathe tidally in seated position, wearing a nose clip, while connected to a pneumotachograph, with closed cabin. The results will be expressed as absolute (kPa x s) and % predicted value, and measured as absolute and relative difference from baseline.

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Feb 2027, 5 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Jan 9, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07329946
Lead sponsor
Pierachille Santus, MD, PhD
Responsible party
Pierachille Santus, MD, PhD (Professor, University of Milan) — Sponsor-investigator
First posted
Jan 9, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 29, 2026

Study contacts

Pierachille Santus Professor, MD, PhD
Contact
pierachille.santus@unimi.it
0039 0239042801
Dejan Radovanovic, MD, PhD
Contact
dejan.radovanovic@unimi.it
0039 0239042372

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Erdosteine

Start the discussion